Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome

This commentary reviews the novel mechanism of action of TRC105 in the context of treatments currently available for metastatic renal cell carcinoma, highlighting the recent findings of Choueiri and colleagues.

Detalles Bibliográficos
Autores principales: Hahn, Andrew W., Pal, Sumanta K., Agarwal, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369955/
https://www.ncbi.nlm.nih.gov/pubmed/30139834
http://dx.doi.org/10.1634/theoncologist.2018-0443
_version_ 1783394273353269248
author Hahn, Andrew W.
Pal, Sumanta K.
Agarwal, Neeraj
author_facet Hahn, Andrew W.
Pal, Sumanta K.
Agarwal, Neeraj
author_sort Hahn, Andrew W.
collection PubMed
description This commentary reviews the novel mechanism of action of TRC105 in the context of treatments currently available for metastatic renal cell carcinoma, highlighting the recent findings of Choueiri and colleagues.
format Online
Article
Text
id pubmed-6369955
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-63699552019-06-20 Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome Hahn, Andrew W. Pal, Sumanta K. Agarwal, Neeraj Oncologist Commentary This commentary reviews the novel mechanism of action of TRC105 in the context of treatments currently available for metastatic renal cell carcinoma, highlighting the recent findings of Choueiri and colleagues. John Wiley & Sons, Inc. 2018-08-23 2019-02 /pmc/articles/PMC6369955/ /pubmed/30139834 http://dx.doi.org/10.1634/theoncologist.2018-0443 Text en © AlphaMed Press 2018
spellingShingle Commentary
Hahn, Andrew W.
Pal, Sumanta K.
Agarwal, Neeraj
Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome
title Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome
title_full Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome
title_fullStr Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome
title_full_unstemmed Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome
title_short Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome
title_sort targeting endoglin to treat metastatic renal cell carcinoma: lessons from osler‐weber‐rendu syndrome
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369955/
https://www.ncbi.nlm.nih.gov/pubmed/30139834
http://dx.doi.org/10.1634/theoncologist.2018-0443
work_keys_str_mv AT hahnandreww targetingendoglintotreatmetastaticrenalcellcarcinomalessonsfromoslerweberrendusyndrome
AT palsumantak targetingendoglintotreatmetastaticrenalcellcarcinomalessonsfromoslerweberrendusyndrome
AT agarwalneeraj targetingendoglintotreatmetastaticrenalcellcarcinomalessonsfromoslerweberrendusyndrome

Ejemplares similares